Cargando…
Eczematous reaction to IVIG for the treatment of dermatomyositis()()
The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116829/ https://www.ncbi.nlm.nih.gov/pubmed/30175220 http://dx.doi.org/10.1016/j.ijwd.2018.03.004 |
_version_ | 1783351660803784704 |
---|---|
author | Berk-Krauss, J. Lee, K. Lo Sicco, K.I. Liebman, T.N. |
author_facet | Berk-Krauss, J. Lee, K. Lo Sicco, K.I. Liebman, T.N. |
author_sort | Berk-Krauss, J. |
collection | PubMed |
description | The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of two female patients with refractory dermatomyositis who developed pruritic, scaly pink plaques after receiving high-dose IVIG. This diffuse eczematous skin reaction to high-dose IVIG is a rare adverse event that most often occurs days after administration of therapy. Practitioners should be aware of this entity because the eczematous eruption may be extensive and can commonly worsen with subsequent re-exposure to IVIG. |
format | Online Article Text |
id | pubmed-6116829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-61168292018-08-31 Eczematous reaction to IVIG for the treatment of dermatomyositis()() Berk-Krauss, J. Lee, K. Lo Sicco, K.I. Liebman, T.N. Int J Womens Dermatol Article The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of two female patients with refractory dermatomyositis who developed pruritic, scaly pink plaques after receiving high-dose IVIG. This diffuse eczematous skin reaction to high-dose IVIG is a rare adverse event that most often occurs days after administration of therapy. Practitioners should be aware of this entity because the eczematous eruption may be extensive and can commonly worsen with subsequent re-exposure to IVIG. Elsevier 2018-06-23 /pmc/articles/PMC6116829/ /pubmed/30175220 http://dx.doi.org/10.1016/j.ijwd.2018.03.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Berk-Krauss, J. Lee, K. Lo Sicco, K.I. Liebman, T.N. Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title | Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title_full | Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title_fullStr | Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title_full_unstemmed | Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title_short | Eczematous reaction to IVIG for the treatment of dermatomyositis()() |
title_sort | eczematous reaction to ivig for the treatment of dermatomyositis()() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116829/ https://www.ncbi.nlm.nih.gov/pubmed/30175220 http://dx.doi.org/10.1016/j.ijwd.2018.03.004 |
work_keys_str_mv | AT berkkraussj eczematousreactiontoivigforthetreatmentofdermatomyositis AT leek eczematousreactiontoivigforthetreatmentofdermatomyositis AT losiccoki eczematousreactiontoivigforthetreatmentofdermatomyositis AT liebmantn eczematousreactiontoivigforthetreatmentofdermatomyositis |